Wave Life Sciences stock fell 2.58 percent as FDA path advances
Wave Life Sciences stock dropped 2.58% to USD 3.78 on October 2, 2026, despite the FDA aligning with a two-year registrational trial for WVE-006, offering a potential accelerated approval path based on biomarker data. This regulatory progress contrasts with a weaker Q2 2026 revenue of USD 2.27 million against an expected USD 7.65 million, and a wider adjusted EPS loss. Analysts maintain a bullish consensus, with an average 12-month target of USD 22.31, even as the stock trades near its 52-week low.
H.C. Wainwright reiterates Buy on Wave Life Sciences stock
H.C. Wainwright has reiterated a Buy rating on Wave Life Sciences (NASDAQ:WVE) stock, maintaining a $13.00 price target. This re-affirmation follows FDA alignment on a single two-year registrational trial for WVE-006, with a one-year biomarker interim analysis supporting potential accelerated approval. Despite the positive outlook from H.C. Wainwright, InvestingPro Tips indicate Wave is rapidly burning through cash, though it maintains a strong current ratio and more cash than debt.
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 in AATD
Wave Life Sciences has announced that the FDA supports its proposed registrational pathway for WVE-006, a potential treatment for alpha-1 antitrypsin deficiency (AATD). The company plans a two-year registrational trial with an interim analysis for accelerated approval based on AATD biomarkers. WVE-006 aims to address both lung and liver manifestations of AATD with a convenient subcutaneous dosing, representing a new standard of care.
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
Wave Life Sciences announced that the FDA supports its planned registrational pathway for WVE-006, an investigational RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD). The company plans a single two-year registrational trial with a one-year interim analysis for potential accelerated approval based on AATD biomarkers. WVE-006 aims to provide a new standard-of-care by addressing both lung and liver manifestations of AATD with a safe and convenient therapy.
Wave Life Sciences Says FDA Feedback Supports Registrational Pathway for WVE-006
Wave Life Sciences announced that it has aligned with the FDA on critical aspects concerning the registrational pathway for its drug candidate, WVE-006. The article indicates that further details are available to premium subscribers.
Wave Life Sciences reaches FDA alignment on WVE-006 trial design
Wave Life Sciences has reached an agreement with the FDA on the trial design for WVE-006, an investigational treatment for alpha-1 antitrypsin deficiency. The company plans a single two-year registrational trial with an interim analysis at one year that could lead to accelerated approval based on biomarkers. WVE-006 is currently being evaluated in a Phase 1b/2a clinical trial, and further data is expected in Q4 2026.
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
Wave Life Sciences announced that the FDA supports its registrational pathway for WVE-006, an investigational RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD). The company plans a two-year registrational trial with a one-year interim analysis for potential accelerated approval based on AATD biomarkers. WVE-006 aims to provide a comprehensive treatment for AATD, addressing both lung and liver manifestations with infrequent subcutaneous dosing.
FDA supports a one-year data check for possible faster approval of Wave's treatment.
Wave Life Sciences (WVE) announced that the FDA supports its proposed registrational pathway for WVE-006, an RNA editing treatment for alpha-1 antitrypsin deficiency (AATD). The plan includes a single, two-year trial with a one-year interim analysis that could lead to accelerated approval based on biomarkers. This approach aims for an efficient path to full approval without a separate confirmatory trial, addressing a high unmet need for the ~200,000 individuals with Pi*ZZ AATD in the U.S. and Europe.
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
Wave Life Sciences announced that the FDA supports its proposed registrational pathway for WVE-006, an investigational RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD). The company plans a two-year registrational trial with a one-year interim analysis for potential accelerated approval based on AATD biomarkers. WVE-006 aims to provide a new standard-of-care treatment for AATD, addressing both liver and lung manifestations with a safe and convenient therapy.
Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
Wave Life Sciences announced that GSK has selected a candidate from their research collaboration for a hepatology indication, which will now transition into GSK's development pipeline. This selection triggers a $12 million milestone payment to Wave, with potential for further development, launch, and commercial milestones up to $375 million per program, plus tiered royalties. The program utilizes Wave’s proprietary SpiNA design GalNAc-siRNA, and three additional collaboration programs are also advancing.
Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development
Wave Life Sciences announced that GSK has selected an siRNA program for a hepatology indication to transition into GSK's development pipeline. This selection triggers a $12 million milestone payment to Wave, with potential for an additional $330-$375 million in milestones and tiered royalties for each collaboration program. The program utilizes Wave's proprietary SpiNA design GalNAc-siRNA, and three other collaboration programs are also advancing towards candidate selection.
Wave Life Sciences Announces GSK Advances Hepatology Candidate from SpiNA siRNA Collaboration
Wave Life Sciences announced that GSK has selected a candidate for a hepatology indication using Wave’s SpiNA design GalNAc-siRNA, triggering a $12 million milestone payment. The collaboration could result in up to $375 million in additional milestones and tiered royalties, with three more programs advancing towards candidate selection. Wave's SpiNA siRNA technology is highlighted for its superior potency and durability, supporting its focus on RNA medicines for various health conditions.
Wave Life Sciences Initiates Phase 2a Trial of Obesity Drug WVE-007 in Combination With Tirzepatide
Wave Life Sciences has initiated a Phase 2a clinical trial for its obesity drug WVE-007, combining it with tirzepatide. This trial aims to assess the efficacy and safety of the combination therapy in treating obesity. The company utilizes its PRISM RNA medicines platform to develop treatments for various disorders.
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
Wave Life Sciences has started a placebo-controlled Phase 2a trial for WVE-007, an investigational GalNAc-siRNA, in combination with weekly tirzepatide for adults with obesity and type 2 diabetes. The company highlights WVE-007's ability to induce fat loss without muscle loss and its potential for once- or twice-yearly dosing. This trial is part of the broader INLIGHT program, which also includes a monotherapy trial and a planned maintenance trial to prevent weight regain after discontinuing incretin therapy.
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
Wave Life Sciences has initiated a Phase 2a clinical trial evaluating WVE-007, an investigational GalNAc-siRNA, in combination with tirzepatide for adults with obesity. The trial aims to assess WVE-007's potential for enhanced fat loss and muscle preservation compared to incretins alone, with preclinical data showing doubled weight loss when combined with GLP-1. This is part of a broader development plan for WVE-007, which also includes monotherapy and post-incretin maintenance trials.
Wave Life Sciences starts Phase 2a obesity trial for WVE-007
Wave Life Sciences has initiated a Phase 2a clinical trial for WVE-007, an investigational GalNAc-siRNA, in combination with tirzepatide for adults with obesity and type 2 diabetes. Preclinical data showed that WVE-007 combined with GLP-1 doubled weight loss and induced fat loss without muscle loss, with potential for annual or semi-annual dosing. This trial is part of a broader program to evaluate WVE-007 in various obesity treatment settings and other metabolic diseases.
JPMorgan resumes Wave Life Sciences stock rating at Neutral
JPMorgan has resumed coverage on Wave Life Sciences (NASDAQ:WVE) with a Neutral rating, citing the company's PRISM platform and its lead asset, WVE-007. The stock is currently trading near its 52-week low after a significant decline. JPMorgan highlighted that the future upside for WVE will largely depend on the success of WVE-007 in obese patients, requiring convincing data beyond initial efficacy.
JPMorgan resumes Wave Life Sciences stock rating at Neutral
JPMorgan has resumed coverage on Wave Life Sciences (NASDAQ:WVE) with a Neutral rating, noting the stock trades near its 52-week low after a significant decline. The firm highlighted Wave's PRISM platform and its lead asset, WVE-007, as key to future upside, pending convincing data on its efficacy in obese patients. While acknowledging other pipeline assets, JPMorgan believes the share performance through 2027 will primarily depend on WVE-007's success.
The executive who led negotiations for Pfizer’s BioNTech vaccine partnership joins Wave
Wave Life Sciences has appointed Monika Vnuk, MD, as its new Chief Business Officer, effective September 2026. Dr. Vnuk brings extensive experience from Sanofi, Blackstone Life Sciences, and Pfizer, where she notably led the negotiation of the COVID-19 vaccine partnership with BioNTech. In connection with her appointment, she received an option to purchase 375,000 Wave common shares, vesting over four years.
Wave Life Sciences appoints Monika Vnuk as chief business officer
Wave Life Sciences has appointed Monika Vnuk, MD, as its new Chief Business Officer. In this newly created role, Dr. Vnuk will oversee business development, corporate development, and alliance management for the clinical-stage biotechnology company. She previously held senior positions at Sanofi, Blackstone Life Sciences, and Pfizer, where she played a key role in the BioNTech COVID-19 vaccine partnership.
Wave Life Sciences stock hits a 52-week low at USD 4.20
Wave Life Sciences (WVE) stock hit a new 52-week low of USD 4.20 on September 22, 2026, before closing at USD 4.26. This comes after the company reported quarterly revenues significantly below analyst estimates and a wider-than-expected loss per share. Despite the poor financial performance, the company appointed a new chief business officer and analysts maintain a "Moderate Buy" rating with a much higher consensus price target of USD 22.31.
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
Wave Life Sciences has appointed Dr. Monika Vnuk as its new Chief Business Officer. Dr. Vnuk brings extensive experience from Sanofi, Blackstone, and Pfizer, and will lead business development, corporate development, and alliance management. This appointment aims to support Wave's continued growth and expand the potential of its RNA medicines platform.
Wave Life Sciences Names Monika Vnuk Chief Business Officer
Wave Life Sciences Ltd. has appointed Dr. Monika Vnuk as its new chief business officer, a newly created role to enhance business development for its RNA medicines platform and pipeline. Dr. Vnuk brings extensive experience from Sanofi, Blackstone Life Sciences, and Pfizer, including leading global partnering and strategic financing. Her appointment is expected to support Wave's growth and expand the reach of its therapeutic programs for various diseases.
Wave Life Sciences appoints Monika Vnuk as chief business officer
Wave Life Sciences Ltd. has appointed Monika Vnuk, MD, as its new Chief Business Officer. In this role, Dr. Vnuk will be responsible for leading business development, corporate development, and alliance management for the biotechnology company. Her extensive background includes senior leadership positions at Sanofi, Blackstone Life Sciences, and Pfizer, where she played a key role in the BioNTech COVID-19 vaccine partnership.
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
Wave Life Sciences will present at the Cantor 2026 Global Healthcare Conference in New York City on September 10, 2026. Paul Bolno, MD, MBA, President and Chief Executive Officer, will participate in an analyst-led fireside chat. A live webcast and archived replay will be available on the company's investor relations website.
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
Wave Life Sciences (Nasdaq: WVE) announced that its President and CEO, Paul Bolno, MD, MBA, will participate in an analyst-led fireside chat at the Cantor 2026 Global Healthcare Conference on September 10, 2026. A live webcast of the presentation will be available on the company's investor relations website, with a replay archived for a limited time. The company is a clinical-stage biotechnology firm focused on RNA medicines for rare and common disorders.
Wave Life Sciences (DB:0VS) - Stock Analysis
Wave Life Sciences (DB:0VS) is a clinical-stage biotechnology company focusing on RNA medicines. The company recently announced positive clinical trial data for its WVE-006 program for Alpha-1 Antitrypsin Deficiency (AATD) and WVE-007 for obesity, showcasing promising results in reducing disease-related proteins and improving body composition, respectively. Despite these advancements and a forecast of 47.4% revenue growth per year, the company is currently unprofitable and has experienced significant shareholder dilution and stock price volatility.
Wave Life Sciences (WVE) Files To Deregister Its Ordinary Shares
Wave Life Sciences (WVE) has voluntarily filed to deregister its Ordinary Shares with the SEC under the Securities Exchange Act of 1934, which will change its reporting obligations and how its shares are handled in public markets. This move, seen as a corporate action, will likely be viewed in terms of how the company plans to fund its RNA medicines pipeline over time, given its heavy R&D spend and reliance on partnerships. Investors should monitor future communications regarding its cash runway and timelines for regulatory discussions and data releases, as these will directly impact its funding story.
WAVE Life Sciences (NASDAQ:WVE) Downgraded by Zacks Research to "Hold"
Zacks Research downgraded WAVE Life Sciences (NASDAQ:WVE) from a "strong buy" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with a $22.53 price target. The company's shares opened near their 52-week low at $5.25, and it reported a quarterly loss and revenue below analyst expectations. Insider selling and institutional ownership details were also highlighted.
Wave Life Sciences (WVE) Files To Deregister Its Ordinary Shares
Wave Life Sciences (WVE) has voluntarily filed to deregister its Ordinary Shares with the SEC under the Securities Exchange Act of 1934, altering its reporting obligations and public market handling. This move, framed as a corporate action, will change how the clinical-stage biotechnology company manages disclosure and funding for its RNA medicines pipeline. Investors are advised to watch how the company communicates future guidance on its cash runway and regulatory discussions, as these will directly impact its funding strategy.
Wave Life Sciences (WVE) Files To Deregister Its Ordinary Shares
Wave Life Sciences (WVE) has filed to deregister its Ordinary Shares with the SEC, a move that will change its reporting obligations and how its shares are handled in public markets. This decision comes as the clinical-stage biotechnology company, with a market cap of $1.1 billion, continues its focus on RNA medicines and significant R&D spend. Investors are advised to monitor the company's communication post-deregistration, particularly regarding its cash runway and timelines for regulatory discussions and data releases.
Wave Life Sciences Inc (HAM:0VS) Stock Price, Trades & News
This article provides a detailed financial overview of Wave Life Sciences Inc (HAM:0VS), a clinical-stage biotechnology company. It covers stock price, key financial metrics like P/E, P/B, market cap, and enterprise value, alongside various performance ranks including financial strength, growth, momentum, and profitability. The report also lists upcoming stock events and addresses frequently asked questions about the company's stock and dividends.
Wave Life Sciences targets fat loss without sacrificing muscle
Wave Life Sciences has advanced its investigational therapy, WVE-007, into Phase 2a of the INLIGHT clinical trial. This therapy aims to reduce body fat while preserving muscle, differentiating itself from current GLP-1 drugs which can lead to muscle loss. The company is also exploring WVE-007's potential for infrequent dosing and its use in combination with or as a maintenance therapy after incretin-based medicines.
Insiders Sold Wave Life Sciences Prematurely At US$13.64 With Stock Trading Higher
This article reports that insiders at Wave Life Sciences sold shares at an average price of US$13.64, a price lower than the current trading price of US$15.93. The analysis suggests that these insiders may have sold prematurely, missing out on further gains, but also notes that insider selling alone is not a definitive indicator of future stock performance.
Wave Life Sciences Ltd. SEC Filing (Aug 17, 2026)
This article reports on an SEC filing by Wave Life Sciences Ltd. (WVE) on August 17, 2026, which is a Notice of Effectiveness with an effective date of August 14, 2026. The filing has a neutral impact and sentiment according to AI analysis. The article also provides recent news and other SEC filings related to Wave Life Sciences, including its redomiciliation to Delaware and insider trading activity.
Wave Life Sciences Inc (HAM:0VS) Stock Price, Trades & News
This page provides a detailed overview of Wave Life Sciences Inc (HAM:0VS) stock, including its current price (€4.96), market capitalization (€864.92M), and various financial metrics such as P/B ratio (2.17) and enterprise value. It highlights key financial strength, growth, momentum, liquidity, and profitability ranks, along with upcoming stock events and warnings about severe warning signs detected by GuruFocus. The company is described as a clinical-stage biotechnology firm focused on RNA medicines to treat rare and prevalent disorders.
Precision Trading with Wave Life Sciences Ltd. (WVE) Risk Zones
This article from Stock Traders Daily provides a detailed analysis of Wave Life Sciences Ltd. (WVE), highlighting weak sentiment across all horizons supporting a short bias. It outlines institutional trading strategies, including long, breakout, and short positions, with specific entry zones, targets, and stop losses. The analysis also features multi-timeframe signal analysis and AI-generated signals for WVE.
Insider Selling: WAVE Life Sciences (NASDAQ:WVE) Director Sells $42,070.00 in Stock
WAVE Life Sciences (NASDAQ:WVE) Director Heidi Wagner sold 7,000 shares of the company's stock for $42,070, reducing her position by 13.48%. The sale occurred amidst weak trading and quarterly results, with WVE shares near their 52-week low and the company reporting a loss and missing revenue estimates. Despite this, analysts maintain a "Moderate Buy" consensus with a significantly higher average target price.
WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe Sells 12,700 Shares
WAVE Life Sciences (NASDAQ:WVE) Director Adrian Rawcliffe sold 12,700 shares of the company's stock for approximately $67,183. The sale occurred on August 12th when shares were trading at $5.29. Following the transaction, WVE shares fell to $5.20, near their 12-month low, and the company reported a quarterly loss and revenue weaker than analyst expectations, though analysts maintain a "Moderate Buy" rating with a target price of $22.53.
Wave Life Sciences (WVE) director’s 3,864-share tax sale under 10b5-1 plan
Ken Takanashi, a director at Wave Life Sciences (WVE), sold 3,864 shares of common stock on August 11, 2026, at a weighted-average price of $6.01 per share. This sale was made under a Rule 10b5-1 trading plan solely to cover tax obligations arising from the vesting of restricted stock units. Following the transaction, Takanashi directly holds 20,079 shares and is associated with 9,606,408 indirect shares through SNBL USA and Shin Nippon Biomedical Laboratories, though he disclaims beneficial ownership beyond pecuniary interest.
Wave Life Sciences (WVE) Stock Looks Cheap After A 68% Fall But Expensive On Sales
Wave Life Sciences (WVE) stock has dropped 68.4% year-to-date, making it seem cheap, yet valuation checks still deem it expensive. The company's recent redomiciliation to Delaware aims to support access to U.S. capital markets, but its P/S ratio of 15.2x, significantly higher than the industry average of 5.0x, suggests overvaluation despite the price drop. The market appears to be highly optimistic about future revenue and execution, raising questions about whether the company can grow into its premium valuation.
Wave Life Sciences Ltd. SEC Filing (Aug 12, 2026)
This article reports on an SEC Form 144 filing by Wave Life Sciences Ltd. (WVE) on August 12, 2026. The filing indicates a proposed sale of 12,700 shares of common stock by an individual, acquired through Restricted Stock Units, with an aggregate market value of $64,071.50. The transaction involves Morgan Stanley Smith Barney LLC as the broker and is scheduled for August 12, 2026.
Watkins Advises Wave Life Sciences on Redomiciliation to Delaware
Latham & Watkins LLP advised Wave Life Sciences, Inc. on its redomiciliation process, changing the parent company from a Singapore entity to a Delaware corporation. This involved a scheme of arrangement under Singapore law, which received shareholder and High Court approvals and was completed on August 7, 2026. The Latham & Watkins team provided expertise across corporate, tax, executive compensation, employee benefits, and public company representation matters.
WAVE Life Sciences (NASDAQ:WVE) Hits New 52-Week Low - Here's What Happened
WAVE Life Sciences (NASDAQ:WVE) shares recently hit a new 52-week low of $5.01 after closing at $6.07, despite analysts maintaining a "Moderate Buy" rating with an average price target of $22.53. The stock decline follows the company reporting weaker-than-expected quarterly results, including a larger loss per share and significantly lower revenue than analyst estimates. Institutional investors have shown mixed activity, with some increasing their stakes while others adjusted positions.
Wave Life Sciences stock hits 52-week low at $5.01
Wave Life Sciences (WVE) stock has dropped to a 52-week low of $5.01, representing a 77% decline from its peak. Despite the significant downturn and recent disappointing Q2 2026 financial results, InvestingPro analysis suggests the stock is undervalued with a fair value of $6.36. The company recently redomiciled to Delaware and anticipates potential catalysts in late 2026, including clinical data and FDA discussions.
Wave Life Sciences Ltd. SEC Filing (Aug 11, 2026)
Wave Life Sciences Ltd. (WVE) filed a Form 144 with the SEC on August 11, 2026. This filing indicates a proposed sale of 7,000 common shares with an aggregate market value of $42,490.00, acquired through the exercise of stock options on the same day. The shares are intended to be sold on NASDAQ through Morgan Stanley Smith Barney LLC.
RA Capital group discloses 16.8% Wave Life Sciences (WVE) ownership after redomiciliation
RA Capital Management, L.P. and affiliated entities have disclosed a 16.8% beneficial ownership stake in Wave Life Sciences (WVE) following the company's redomiciliation on August 7, 2026. This ownership, totaling 34,314,406 shares, includes common stock held directly by their fund, shares issuable from Pre-Funded Warrants, and additional shares and options held by Dr. Peter Kolchinsky. The redomiciliation involved Wave Life Sciences, Inc. (Delaware) becoming the ultimate parent company, with Wave Life Sciences Ltd. (Singapore) becoming a wholly-owned subsidiary through a share exchange.
WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 6.8% - Should You Sell?
WAVE Life Sciences (NASDAQ:WVE) shares recently dropped 6.8% to $5.66 after the company reported weaker-than-expected quarterly results, including a wider loss per share and lower revenue than projected. Despite the stock trading below its moving averages and remaining unprofitable, analysts maintain a "Moderate Buy" consensus rating with an average target price significantly higher than its current trading price. Institutional investors have also shown increased interest, adjusting their positions in the company.
Wave Life Sciences: WVE-007 and AATD programs are set for major clinical and regulatory milestones in the coming year
Wave Life Sciences' WVE-007 and AATD programs are expected to reach significant clinical and regulatory milestones within the next year. The company's strategic partnerships and strong financial standing are supporting ongoing clinical progress and a planned expansion into cardiometabolic indications. These updates were highlighted at a Bank of America SMID Cap Virtual Conference.
Wave Life Sciences Announces Completion of Redomiciliation to Delaware Corporation
Wave Life Sciences has successfully completed its redomiciliation from Singapore to a Delaware corporation, with the change taking effect after trading on August 7, 2026. All shares of the Singapore entity were exchanged for shares of the new Delaware corporation on a one-for-one basis, and the stock will continue to trade under the "WVE" symbol on NASDAQ. The company anticipates no material impact on its employees or operations and continues its focus on RNA medicines for various health conditions.
